Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized Trial
Top Cited Papers
Open Access
- 14 July 2004
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (2) , 191-201
- https://doi.org/10.1001/jama.292.2.191
Abstract
Highly active antiretroviral therapy has transformed human immunodeficiency virus (HIV) infection into a chronic manageable disease.1-3 However, although many regimens lower plasma viral load to below the limit of detection in most patients, maintaining a durable response remains challenging because of adverse effects, long-term toxicity, and complex dosing schedules, all of which can lead to nonadherence, virologic failure, and drug resistance.4-6Keywords
This publication has 12 references indexed in Scilit:
- Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy–Naive and –Experienced Patients Coinfected with HIV‐1 and Hepatitis B VirusThe Journal of Infectious Diseases, 2004
- Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individualsAIDS, 2003
- Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DFAIDS, 2002
- Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination TherapyThe Journal of Infectious Diseases, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89Antimicrobial Agents and Chemotherapy, 1997
- Decline in deaths from AIDS due to new antiretroviralsThe Lancet, 1997
- Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 yearsAntimicrobial Agents and Chemotherapy, 1997